Full Text | PDF

Share on tweeters Share on facebook Share on linkedin Share on googleplus

Int J Med Sci 2022; 19(14):2087-2092. doi:10.7150/ijms.79162 This issue Cite

Review

Can CD147 work as a therapeutic target for tumors through COVID-19 infection?

Hao-Lin Ren1, Gui-Min Wen2, Zhen-Ying Zhao3, Da-Hua Liu4, Pu Xia4✉

1. Department of Radiology, the First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, P.R. China.
2. Department of Basic Nursing, College of Nursing, Jinzhou Medical University, Jinzhou, Liaoning, P.R. China.
3. Department of Pharmacy, Tianjin Union Medical Center, Tianjin, P.R. China.
4. Biological Anthropology Institute, College of Basic Medicine, Jinzhou Medical University, Jinzhou, Liaoning, P.R. China.

✉ Corresponding author: Pu Xia, PhD, Biological Anthropology Institute, College of Basic Medicine, Jinzhou Medical University, Jinzhou 121001, P.R. China. E-mail: xiapuEDU.CN.

Citation:
Ren HL, Wen GM, Zhao ZY, Liu DH, Xia P. Can CD147 work as a therapeutic target for tumors through COVID-19 infection?. Int J Med Sci 2022; 19(14):2087-2092. doi:10.7150/ijms.79162. https://www.medsci.org/v19p2087.htm
Other styles

File import instruction

Abstract

Graphic abstract

In this review, we discussed an interesting case infected with “COVID-19” (Corona Virus Disease 2019). The patients with Hodgkin's lymphoma recovered after infection with COVID-19. It may be that COVID-19 activates the patient's immune system, or it may be a coincidence. COVID-19 spike protein can interact with CD147 and use it as an entry to invade host cells. CD147 is a partner of SLC3A2, which is the chaperone subunit of cystine/glutamate reverse transporter (system XC). The catalytic subunit of system XC is SLC7A11. SLC7A11 mediated cysteine uptake plays a key role in ferroptosis. Through literature review and data analysis, we suggest that CD147, as a new potential COVID-19 infection entry, may also lead to ferroptosis of host cells. Our hypothesis is that spike protein of COVID-19 induced ferroptosis in host cells via CD147/SLC3A2/SLC7A11 complex. This is another explanation for the cancer patient recovered after COVID-19 infection.

Keywords: ferroptosis, CD147, cancer, COVID-19, SLC7A11

Citation styles

APA
Ren, H.L., Wen, G.M., Zhao, Z.Y., Liu, D.H., Xia, P. (2022). Can CD147 work as a therapeutic target for tumors through COVID-19 infection?. International Journal of Medical Sciences, 19(14), 2087-2092. https://doi.org/10.7150/ijms.79162.

ACS
Ren, H.L.; Wen, G.M.; Zhao, Z.Y.; Liu, D.H.; Xia, P. Can CD147 work as a therapeutic target for tumors through COVID-19 infection?. Int. J. Med. Sci. 2022, 19 (14), 2087-2092. DOI: 10.7150/ijms.79162.

NLM
Ren HL, Wen GM, Zhao ZY, Liu DH, Xia P. Can CD147 work as a therapeutic target for tumors through COVID-19 infection?. Int J Med Sci 2022; 19(14):2087-2092. doi:10.7150/ijms.79162. https://www.medsci.org/v19p2087.htm

CSE
Ren HL, Wen GM, Zhao ZY, Liu DH, Xia P. 2022. Can CD147 work as a therapeutic target for tumors through COVID-19 infection?. Int J Med Sci. 19(14):2087-2092.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2024 Ivyspring International Publisher. Terms of use